Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon

Recaps

I Can Extract Side Effects
VolumesArcsSummaries

Arc 11The Gene Patent War

Wei Kang and Sanqing faced patent lawsuits and a blocked Eagle Country market while developing a new gene-editing technology. The conflict eased as the Broad Institute withdrew its suit, and Syngenta expanded Super Soybean sales abroad while Sanqing shifted its Feizhou drug strategy toward local partnerships and aid.

  • Consumers rushed to buy domestic cooking oil after Super Soybean’s record yield drew attention, and Wei Kang praised General Manager Wang’s publicity campaign.
  • Wei Kang tasked Tang Que with finding an independent gene-editing tool, and Three Purities’ Gene Laboratory began working with the China Academy of Sciences.
  • Zheng Feng and Wei Kang settled the Broad Institute’s first patent dispute by agreeing that Sanqing would pay 25% of profits on each Thalassemia Gene Drug sold.
  • After the Broad Institute filed suit and the FDA halted Sanqing’s Eagle Country sales, Tang Que revealed a new protease from an ancient Antarctic bacterium and a promising upgraded gene drug.
  • Zheng Feng joined forces with Dr. Dudna to revoke Sanqing’s CRISPR licenses, but Three Purities won the Chinese jurisdiction dispute and the Broad Institute later withdrew its lawsuit.
  • Wang De secured a Tanzanian agreement for farmers to grow Super Soybeans for guaranteed purchase, then negotiated seed and fertilizer sales with other foreign delegations.
  • After the WHO removed Three Purities from its prequalified medicines list, Wei Kang withdrew its application and directed Zhang Chunming to pursue government cooperation, pharmacies, and aid organizations.
  • Zhang Chunming arranged for Sanqing medicines to be donated or sold at cost to secure the release of Zhu Shan and two other Chinese men held in Zhongfei Country.
Chapters 251–275 Vol. 3 Read

Ch. 251The Soybean War, We've Definitely Won

News about Super Soybean’s experimental yield of 1,000 jin per mu sparked patriotic support for domestic products and renewed attention to China’s soybean industry. At Sanqing Headquarters, Wei Kang welcomed the publicity campaign as a strong start to promoting the seeds and expanding their supply chain.

  • Reports about Super Soybean’s record experimental yield spread online, prompting netizens to discuss foreign control of the soybean trade and call for support of domestic products.
  • Self-media articles recounted how international grain traders had gained control of China’s soybean-processing industry and declared that Super Soybean could help China win the food war.
  • Consumers rushed to buy domestic cooking oil, Fortune Gate’s sales surged, and Golden Dragon Fish faced a sharp backlash.
  • At Sanqing Headquarters, Wei Kang praised General Manager Wang’s publicity campaign for making Super Soybean widely known.
  • Wei Kang expected Syngenta to promote Super Soybean with downstream processors, while growers, grain traders, and national policy support helped build the industry chain.
Read chapter

Ch. 252If there is no long-term planning, there will be immediate worries

Huang Qin reported Three Purities’ progress developing gene-edited crops, prompting Wei Kang to address the patent risks of CRISPR-Cas9. Wei ordered Tang Que to lead a search for an independent gene-editing tool while Huang continued improving Super Soybean production, and Three Purities began coordinating with the China Academy of Sciences and Syngenta.

  • Huang Qin told Wei Kang and Tang Que that Three Purities had developed gene-edited soybeans, corn, rice, peanuts, and other crops in collaboration with Syngenta.
  • Wei Kang raised patent concerns about CRISPR-Cas9, and Huang Qin explained why ZFN and TALEN were unsuitable for economical industrial-scale crop breeding.
  • Tang Que proposed screening bacteria for new gene-editing proteases, and Wei Kang ordered him to form a dedicated team while Huang continued developing Super Soybean mass-production technology.
  • Tang Que suggested searching Archaea as well as bacteria, and Wei Kang said he would seek help from the China Academy of Sciences.
  • After the meeting, Wei Kang contacted Academician Chang and Wang De, and Three Purities’ Gene Laboratory began working with the China Academy of Sciences to develop an independent gene-editing tool.
Read chapter

Ch. 253They're Anxious, and They Are Too

Li Dong and Xiao Wang investigated counterfeit Syngenta seeds in Wan Province, where a shop owner revealed the cross-regional network behind seed relabeling and urged them to trace it to Ili. Meanwhile, Cargill and three other grain traders confirmed China’s Super Soybean was real and feared losing China’s soybean market.

  • Li Dong identified counterfeit Heyu 187 seeds at a Lu City shop, but the owner replaced them with genuine bags after suspecting that Li Dong and Xiao Wang were Syngenta investigators.
  • The shop owner asked whether Syngenta’s Super Soybean could yield a thousand jin per mu, and Li Dong confirmed the crop was real while clarifying that field results were still pending.
  • The owner offered details about the counterfeit-seed supply chain, explaining that infringing seeds crossed regions and that their production bases in Ili needed to be targeted.
  • At Cargill headquarters, Wallace asked his executives whether China’s Super Soybean was real, and ADM president Patricia confirmed it through information from COFCO and Yihai Group.
  • Patricia told Wallace and the other grain-trader presidents that Syngenta and Sanqing Group had developed Gene Editing crops, and they agreed China’s Super Soybean threatened their market and would lead to a major conflict.
Read chapter

Ch. 254The Impossible Mission

Huang Qin discussed gene-editing patents and research with Williams, who became convinced that Three Purities’ development software might be true artificial intelligence. Williams reported his suspicion to his contacts, who ordered him to obtain a copy of the company’s secrets at any cost, leaving him to realize he had become expendable.

  • Huang Qin told Williams that Three Purities needed to explore alternatives to CRISPR-Cas9 because its patent fees could expose them to pressure from Eagle Country.
  • Williams wondered why Three Purities’ research progressed so smoothly, and Huang Qin credited the company’s capable staff and dismissed the idea that its software was true artificial intelligence.
  • Williams suspected the software was AI and, after work, sent the suspicion to his contacts using a hidden computer in his dormitory.
  • Williams’s contacts ordered him to obtain a copy of Three Purities’ secrets at any cost, and he realized they were willing to sacrifice him.
Read chapter

Ch. 255FDA's Proactive Invitation

Saul and Chris planned to exploit Three Purities’ gene-editing patents and lure the company into Eagle Country, while the FDA invited its thalassemia therapy for trials. Wei Kang agreed to consider the invitation only if the FDA lifted a painkiller ban and fast-tracked other drugs, and the FDA approved those conditions while retaining the right to reinstate the ban.

  • Saul and Chris discussed verifying intelligence that Three Purities used advanced artificial intelligence and obtaining a copy for analysis.
  • Saul urged Chris to find a way to retaliate against Three Purities over the Super Soybean matter, and Chris proposed suing over CRISPR-Cas9 patents.
  • Chris explained that the Zheng Feng Laboratory held the patent and that Three Purities could not be sued unless it brought Super Seed to Eagle Country, so they agreed to first ask Mr. Pawn which gene-editing tools its therapies used.
  • Wei Kang received the FDA’s invitation to conduct Eagle Country clinical trials for Three Purities’ thalassemia gene therapy and conditioned his agreement on lifting the painkiller ban and fast-tracking other drugs.
  • Davis submitted Wei Kang’s conditions for approval, and the FDA agreed to lift the painkiller ban temporarily while keeping the option to restore it.
Read chapter

Ch. 256New Drug for Anemia Launched Overseas

Three Purities began overseas trials for its new drugs after the FDA eased restrictions and fast-tracked approvals. In Eagle Country, patients welcomed a newly available non-addictive painkiller, while Solomon was finally invited to join the Thalassemia Gene Drug trial at Mayo Clinic.

  • Wei Kang was surprised that the FDA had lifted the painkiller ban, accepted Chinese clinical data, and bundled Three Purities' drug applications for fast-track review.
  • Three Purities launched overseas trials, and the Thalassemia Gene Drug entered Phase III through the FDA's rare-disease green channel with only a few dozen participants needed.
  • In West Virginia, Alexander asked his doctor for more painkillers, and the doctor prescribed a newly available non-addictive drug instead.
  • Alexander learned the FDA had previously banned the new painkiller and angrily vowed to expose the agency online.
  • In California, Solomon received a call inviting him to join the Thalassemia Gene Drug's Phase III trial in Eagle Country at Mayo Clinic.
Read chapter

Ch. 257The Patent Big Stick Is Stirring

Wei Kang reviewed the Thalassemia Gene Drug’s successful trials and the unresolved CRISPR patent dispute in Eagle Country, then Three Purities launched the drug there for $500,000. Saul prepared to use alleged CRISPR evidence and the patent dispute to sue Three Purities after patients completed treatment and paid.

  • Wei Kang examined the trial results, confirmed the drug had cured patients, and checked Three Purities’ patent licenses amid the dispute between the University of California team and the Broad Institute.
  • Wei Kang concluded Three Purities had acted legally and decided to wait for any patent challenge.
  • Three Purities launched the Thalassemia Gene Drug in Eagle Country for $500,000, drawing praise from patients and netizens.
  • Saul asked about evidence collection, and his contact said a hospital had withheld gene drugs containing CRISPR-Cas9 agents as evidence.
  • Saul told his contact to wait until the first patients completed treatment and paid before filing suit, and said his patent club was ready to strike.
Read chapter

Ch. 258Soybean Harvest, A Lawsuit

Syngenta celebrated record Super Soybean yields, but the Broad Institute’s patent lawsuit against Three Purities threatened to delay mass production. After learning of the dispute, Tang Que rallied the Gene Laboratory team to develop an independent gene-editing technology.

  • Wang De celebrated a Heilongjiang Super Soybean yield of 938 jin per mu and learned that test plots in Xinjiang reached 956 jin.
  • Syngenta reported the harvest results, prompting nationwide excitement and a surge of demand for Super Soybean seeds ahead of spring planting.
  • Wang De learned from Wei Kang that the Broad Institute had sued Three Purities over its Thalassemia Gene Drug, creating patent concerns for commercialization.
  • Wang De decided to sell Super Soybean domestically, initially focusing on the Northeast, and said Syngenta would contest the patent dispute.
  • Wenren Long told Tang Que about the lawsuit, and Tang Que gathered the Gene Laboratory team and urged them to develop a new gene-editing technology by screening Archaea and wild bacteria.
Read chapter

Ch. 259Patent Strangulation Against the Three Purities, First Reconciliation

Zheng Feng signed a $1.5 billion gene-editing partnership with Pfizer and plotted to use patent fees and a drawn-out lawsuit against Three Purities while developing a competing thalassemia treatment. After Durand approved the strategy and tied it to Eagle Country’s effort to preserve its scientific lead, Zheng Feng prepared to meet Wei Kang at the first settlement meeting.

  • Zheng Feng reviewed and signed a $1.5 billion partnership contract with Pfizer’s Dostan to develop gene therapies for rare diseases.
  • Dostan asked Zheng Feng to help advance treatments for Beta-Thalassemia and Sickle Cell Disease, and Zheng Feng agreed to draw on Three Purities’ research.
  • Zheng Feng proposed collecting patent fees from Three Purities while delaying the lawsuit until Pfizer and his company developed a competing drug.
  • Zheng Feng recalled his rise from immigrant student to celebrated scientist and credited his mentor Durand’s influence for helping him win the CRISPR patent dispute.
  • Durand approved Zheng Feng’s strategy against Three Purities and urged him to use any means necessary to protect Eagle Country’s scientific advantage.
  • Zheng Feng told Durand he would meet Three Purities’ boss, Wei Kang, at their first out-of-court settlement meeting the next day.
Read chapter

Ch. 260Reaching a Reconciliation

Zheng Feng and Sanqing negotiated a settlement over the Broad Institute’s CRISPR patent infringement claims, with Wei Kang observing remotely. They reached a preliminary agreement for Sanqing to pay 25% of profits on Thalassemia Gene Drugs sold, but both sides expected the dispute to continue.

  • Yang Haoran introduced Zheng Feng and Wei Kang at the start of the settlement negotiations.
  • The Broad Institute accused Sanqing of patent infringement and demanded an apology, licensing fees, and up to two billion dollars in damages.
  • Sanqing’s lawyers challenged the Broad Institute’s patent rights and argued that Sanqing had tried to negotiate a license, while Yang Haoran refused to apologize.
  • Zheng Feng offered to drop the apology demand if Sanqing paid patent fees, and Wei Kang accepted the proposal.
  • After bargaining over how the fees would be calculated, the sides agreed that Sanqing would retroactively pay 25% of profits on each Thalassemia Gene Drug sold.
Read chapter

Ch. 261The Outrageously Low Patent Fee

After Sanqing Group settled its patent lawsuit with the Broad Institute, the 25% licensing rate triggered industry alarm and public outrage. Wei Kang learned that the Thalassemia Gene Drug had received expedited domestic approval, and he resolved to lead Sanqing against its opponents.

  • After Sanqing Group and the Broad Institute settled out of court, Zheng Feng reassured other biotech companies that they would not face Sanqing’s 25% licensing rate.
  • Chinese netizens condemned the Broad Institute and Zheng Feng online, debated the patent dispute’s impact, and called for domestic gene-editing tools.
  • Wei Kang received word that the Thalassemia Gene Drug had passed review and could launch domestically the next day.
  • Wei Kang suspected the Broad Institute’s actions were part of pressure connected to Super Soybean and resolved to make Sanqing strong enough to deter future attacks.
Read chapter

Ch. 262The Ridiculously Low Patent Fee (Part 2)

Sanqing Group refunded Thalassemia patients after cutting the gene drug’s price in half, while Zheng Feng discovered that the Broad Institute had received only $125,000 in patent fees. The chapter ended with Zheng Feng learning that Three Purities planned to keep profits low for years.

  • Bart feared he could not afford his treatment until Sanqing Group called to announce a 50 percent discount and refunded him $75,000.
  • Other Thalassemia patients received refunds, prompting new patients to seek treatment, but doctors said the queue had grown beyond a thousand people and wait times were three years.
  • Zheng Feng checked the Broad Institute’s account on the patent-fee deadline and found a payment of only $125,000 from Three Purities.
  • Zheng Feng’s subordinate explained that the fee reflected roughly 200 treatments and low reported profits, and said Three Purities expected profits to rise only after costs were recovered.
  • Zheng Feng nearly fainted when he heard Three Purities had told the institute to wait several years to earn more.
Read chapter

Ch. 263Another Lawsuit?

Zheng Feng found that Three Purities had structured the Thalassemia Gene Drug’s pricing to leave little patent profit, while Wei Kang secured a friendlier CRISPR licensing deal with the University of California team. Wei Kang and Jian Lianyun enjoyed their growing relationship until he learned the Broad Institute had abandoned its settlement and filed suit against Three Purities.

  • Zheng Feng examined Three Purities’ low reported profit and went to seek a new strategy from his mentor, Durand.
  • Three Purities launched its Thalassemia Gene Drug in China and agreed with the University of California team to pay patent fees when sales reached specified milestones.
  • Wei Kang explained to Jian Lianyun that he had accepted losses in Eagle Country to resist the Broad Institute, relying on the China and Europa markets instead.
  • Wei Kang and Jian Lianyun shared a meal and spent a quiet evening together, keeping their relationship mostly private.
  • Yang Haoran called Wei Kang to report that the Broad Institute had withdrawn from its settlement and filed a lawsuit, though negotiation remained possible at a high cost.
Read chapter

Ch. 264Exorbitant Patent Fees

Three Purities and the Broad Institute resumed patent negotiations after the Institute demanded an upfront $50 million fee and steep royalties, threatening a multibillion-dollar lawsuit. Wei Kang suspected the lawsuit was mainly leverage and ordered Yang Haoran to keep negotiating and bargain down the price, leaving the talks to his team.

  • Zheng Feng accused Three Purities of using its patent fees to fund patient discounts, and the Broad Institute's lawyer demanded $50 million upfront, 20 percent of net Eagle Country sales, and threatened a $2 billion lawsuit.
  • Yang Haoran and Three Purities' lawyer objected to the demands, while the Broad Institute's lawyer cited its Pfizer deal and argued that patent infringement penalties could exceed $2 billion.
  • After Three Purities' lawyer warned that Eagle Country courts could impose severe damages, Yang Haoran and the legal team urged Wei Kang to settle rather than risk litigation.
  • Wei Kang questioned why the Broad Institute kept negotiating if it was certain to win, concluding that it wanted money without forcing Three Purities' drug out of the Eagle Country market.
  • Wei Kang told Yang Haoran to prolong the negotiations and drive the price down, then left his team to continue the talks.
Read chapter

Ch. 265Major Breakthrough, Negotiations Collapse

Wei Kang realized the Broad Institute and Pfizer might be preparing to use Three Purities’ clinical progress to enter the Thalassemia Gene Drug market, and decided to withdraw from Eagle Country. Before he could act, Tang Que reported discovering a new gene-editing protease, while Zheng Feng ordered settlement talks stopped and a patent lawsuit filed after Pfizer’s drug showed promising trial results.

  • Wei Kang suspected the Broad Institute and Pfizer were collaborating to develop a Thalassemia Gene Drug using Three Purities’ work, so he decided to pull out of the Eagle Country market and fight them.
  • Tang Que called Wei Kang to announce that Three Purities had discovered a new gene-editing protease, and Wei Kang rushed to the Gene Laboratory.
  • Dostan presented Pfizer executives with a Thalassemia Gene Drug made using technology from the Broad Institute, and reported that treated cells had produced normal hemoglobin.
  • Zheng Feng learned Pfizer’s first patient trial had succeeded and celebrated the drug’s potential market value.
  • Zheng Feng ordered his subordinate to suspend settlement negotiations with Three Purities and immediately file a patent infringement lawsuit.
Read chapter

Ch. 266One Blow After Another

Broad Institute sued Sanqing Group for patent infringement, forcing it to halt Thalassemia Gene Drug sales in Eagle Country and disrupting patients’ treatment. Broad Institute and Pfizer then announced their own drug, while Chinese netizens rallied behind Sanqing.

  • CNN reported that Broad Institute demanded up to $2 billion from Sanqing and sought to stop its commercial use of the disputed technology.
  • The FDA ordered Yang Haoran to stop Sanqing’s Eagle Country sales and submit patient records, while patients had appointments canceled and ongoing treatment suspended.
  • A patient protested being denied Sanqing’s drug, and Thalassemia patients gathered outside FDA headquarters.
  • Zheng Feng and Dostan announced that Broad Institute and Pfizer were jointly developing a Thalassemia Gene Drug and invited patients to apply for clinical trials.
  • Eagle Country patients returned home to seek Pfizer’s trial treatment, while Chinese netizens condemned the move and sent messages of support to Sanqing and Wei Kang.
Read chapter

Ch. 267Patent Backstab

Zheng Feng reconciled with Dr. Dudna by offering to share the CRISPR patent, but secured her support for revoking Sanqing Group’s licenses and blocking its commercial research. Sanqing Group faced a new lawsuit in China as the conflict with the Broad Institute escalated.

  • Zheng Feng offered Dr. Dudna shared ownership of the CRISPR patent in exchange for revoking Sanqing Group’s license and joining forces with him.
  • Zheng Feng revealed that Dr. Carpenti had agreed to the plan after being persuaded by Margarita Louis Dreyfus, and Dr. Dudna accepted the proposed partnership after negotiating its terms.
  • Several days later, Zheng Feng announced that his team and Dr. Dudna’s team would jointly own the CRISPR patent and revoke Sanqing Group’s licenses for commercial development.
  • Zheng Feng filed a lawsuit against Sanqing Group in China, leaving the company under attack from both sides.
Read chapter

Ch. 268A New Generation of Gene Editing Tools Emerges

Wei Kang learned that Tang Que had developed a precise, versatile gene-editing tool from an ancient Antarctic bacterium and used it to create a Thalassemia gene drug suitable for direct injection. After Sanqing faced a patent-infringement lawsuit intended to delay the drug’s launch, Wei Kang set the summons aside and prepared to fight.

  • Tang Que told Wei Kang that his team had discovered a powerful gene-editing protease in the Original Long Rod Bacterium, an ancient Antarctic microbe.
  • Tang Que explained that the protease enabled precise, efficient editing and could be adapted to treat Thalassemia without requiring bone marrow transplantation.
  • Tang Que said Sanqing had created a new Thalassemia gene drug that performed well in cell experiments and could be injected directly into patients.
  • Tang Que worried that Sanqing might use its patent to impose excessive fees, and Wei Kang assured him that the company would not follow the Broad Institute’s example.
  • Wei Kang returned to his office and found that the University of California team’s domestic branch had sued Sanqing in Kun City over its Thalassemia gene drug.
  • Wei Kang dismissed the summons and declared that he was ready for a fight.
Read chapter

Ch. 269If You Want War, Then War It Shall Be

During a live interview, Zheng Feng lost his composure when Sanqing announced a new gene-editing technology that bypassed CRISPR patents, forcing him to retreat from his attacks. In China, Li Han canceled a paid smear campaign and ordered his team to promote Sanqing instead.

  • Zheng Feng told Kelly that Sanqing had infringed on CRISPR patents and promoted Pfizer's new thalassemia drug during their interview.
  • Kelly confronted Zheng Feng with Sanqing's announcement of a Fourth Generation Gene Editing Technology and its upgraded thalassemia drug, leaving him stunned.
  • Kelly read Wei's declaration, “Nǐ yào zhàn, nà biàn zhàn!”, and pressed Zheng Feng about the coming conflict; Zheng Feng denied any war and ended the interview.
  • Li Han watched Sanqing's announcement and stopped his team from launching the overseas-funded smear campaign.
  • Li Han ordered his team to return the deposit, expose the client's scheme, and publish praise for Sanqing.
Read chapter

Ch. 270Overnight Patent Law Revisions

Three Purities countered the Broad Institute’s patent lawsuits with antitrust cases and threatened to withdraw its medicines from Eagle Country after the FDA rejected its application. The Broad Institute withdrew its lawsuit, but Durand secretly pursued a patent bill designed to block Three Purities’ new technology from competing in Eagle Country.

  • Three Purities won jurisdiction in Kun City and had its patent infringement claim dismissed, then filed patent abuse and antitrust suits against the Broad Institute in Eagle Country.
  • The FDA rejected Three Purities’ application for its Thalassemia Gene Drug, so Three Purities announced it would suspend sales of its medicines in Eagle Country; patients and influential customers protested the decision.
  • Wei Kang told Pfizer’s Andre that Three Purities could end their anticancer drug partnership, prompting Andre to promise to seek support for fair treatment and express interest in licensing Three Purities’ gene-editing technology.
  • Durand advised Zheng Feng to stop fighting the old patent battle, then revealed plans for a bill that would restrict foreign patent applications and prioritize university patents to hinder Three Purities’ new technology.
  • The Broad Institute withdrew its patent lawsuit, and Three Purities made no further comment as people around the world reacted to the sudden end of the dispute.
Read chapter

Ch. 271Super Soybean Blossoms Overseas

Wang De presented Syngenta’s plan to expand Super Soybean cultivation in Feizhou, starting with a guaranteed-purchase agreement in Tanzania. After signing the contract, he traveled to Ethiopia, where Jemol and other African Union agriculture ministers awaited him.

  • Wang De told Syngenta executives that Three Purities’ gene-editing technology cleared patent barriers and that Super Soybean could help China diversify its soybean imports through Feizhou.
  • Wang De and the executives discussed developing the Tanzanian market with COFCO, using Chinese funding and technology and Super Soybean seeds adapted to the region.
  • Kendam rejected Bunge’s request to negotiate, citing its unpaid compensation for an earlier breached soybean contract, and prepared to welcome the Chinese delegation.
  • Kendam received Wang De and the Syngenta and COFCO representatives, and the parties signed a tripartite agreement for Tanzanian farmers to grow Super Soybeans for guaranteed purchase.
  • Wang De traveled to Ethiopia, where Jemol and a group of African Union agriculture ministers greeted him and expressed anticipation for Super Soybean.
Read chapter

Ch. 272Seed War, Delivering Warmth to Their Doorstep

After China opened genetically modified crop cultivation, Wang De recognized an opportunity to supply Bear Country, whose seed imports were threatened by Western sanctions. He hosted Bear Country seed representatives at Syngenta’s production base, where they inspected Super Seeds and negotiated a large discounted order.

  • China approved genetic safety certificates for multiple crop varieties and opened genetically modified crop cultivation, prompting a surge of investment in the seed industry.
  • After Bayer halted seed sales to Bear Country and neighboring nations, Wang De welcomed the news as an opportunity for Syngenta.
  • Wang De led Zelny and Bear Country seed-company representatives through Syngenta’s displays and experimental fields, where they examined Super Seeds suited to their needs.
  • Zelny praised the seeds and negotiated a discounted bulk purchase with Wang De, who also offered rapid delivery and potential grain purchase orders through COFCO Group.
Read chapter

Ch. 273The Four Grain Giants' Mounting Defeats

Syngenta secured a huge fertilizer contract from agricultural companies in Samba Country and Argentina, using its supply links with Bear Country to profit from global shortages. The four major grain merchants accepted that their companies would keep buying supplies through Syngenta, then agreed to target Three Purities’ generic medicines in Feizhou.

  • Wang De won a large, long-term fertilizer contract from trade delegations representing agricultural companies in Samba Country and Argentina, alongside interest in Super Seeds.
  • Wang De arranged to resell Bear Country fertilizer through Syngenta, filling Latin American demand after Bear Country and White-Haired Country’s exports were disrupted.
  • Wallace, Margarita, Patricia, and Bunge’s chief executive officer argued over their companies’ losses in Bear Country and Feizhou, then acknowledged that Latin American subsidiaries had bought fertilizer and seeds from Syngenta.
  • Patricia proposed keeping those purchases quiet, and the other executives agreed to continue buying supplies despite possible sanctions.
  • Margarita proposed using influence over Feizhou’s generic-medicine procurement to target Three Purities, and Wallace offered his cousin’s international connections to help.
Read chapter

Ch. 274WHO Rejects Three Purities Generic Drugs

Zhang Chunming traveled to Kenya to bid Three Purities’ generic medicines, but discovered that WHO had removed the company from its prequalified medicines list and blocked its tender entry. After learning the review would take at least six months, Wei Kang ordered Three Purities to withdraw its application and stop dealing with NGOs.

  • Zhang Chunming met his Kenyan agent Taji and prepared Three Purities’ bid, confident its WHO prequalification and medicine quality would satisfy the tender organizers.
  • Taji explained how locals diluted Three Purities’ painkillers in cough syrup, and Zhang Chunming was stunned by the improvised use.
  • A tender official rejected Zhang Chunming’s presentation, claiming Three Purities had been removed from the WHO prequalified medicines list.
  • Zhang Chunming checked the WHO website, confirmed the removal, and went to the WHO office in Kenya for an explanation.
  • A WHO representative said Three Purities had missing documentation, would need another on-site review within six months, and could not use its previous review results meanwhile.
  • Wei Kang told Zhang Chunming to withdraw the application, seek a refund, avoid NGOs, and rely on Chinese aid organizations, public institutions, and Three Purities’ own charitable foundation.
Read chapter

Ch. 275A Sudden Kidnapping

After the WHO rejected Sanqing’s drugs, Wei Kang redirected the company toward other sales channels, and Zhang Chunming helped its medicines gain a strong reputation in Feizhou. That reputation helped secure the release of three kidnapped Chinese men, who returned safely after Sanqing supplied their captors with medicine.

  • Wei Kang withdrew Sanqing’s drugs from the WHO process, and Zhang Chunming obtained refunds and sought ways to sell the medicines through government cooperation and pharmacies.
  • Zhang Chunming expanded Sanqing’s sales in Feizhou through local representatives and the popularity of medicines used by China’s medical aid teams.
  • A subordinate told Zhang Chunming that three Chinese men had been taken in Zhongfei Country and that their captors demanded Sanqing medicines instead of money.
  • Zhang Chunming arranged for Sanqing to donate some medicines and provide others at cost, then sent the shipment to Zhongfei Capital.
  • Zhu Shan and the two other men reunited with their relatives and friends after the captors inspected the medicines and drove away with the truck.
  • Zhu Shan explained that the captors had treated them well because they needed medicines, and the group expressed pride in Sanqing and China.
Read chapter
Arc 11 of 27
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS